Premium
Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma
Author(s) -
Lipton Allan,
Harvey Harold A.,
Lawrence Bellarmine,
Gottlieb Robert,
Kukrika Miodrag,
Dixon Richard,
Graham William,
Miller Stephen,
Heckard Robert,
Schelzel Dale,
White Deborah S.
Publication year - 1983
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19830101)51:1<57::aid-cncr2820510114>3.0.co;2-v
Subject(s) - medicine , corynebacterium parvum , melanoma , adjuvant , immunotherapy , microbiology and biotechnology , immunology , cancer research , immune system , biology
Abstract One‐hundred and sixteen patients with Stage I and Stage II malignant melanoma were randomized to treatment with either Bacillus Calmette‐Guerin (BCG) (Tice) or subcutaneous Corynebacterium parvum (Burroughs‐Wellcome). Life table analysis failed to reveal a difference between these two forms of treatment in 68 Stage I patients. The relapse rate was significantly reduced in Stage II patients trated with C. parvum.